IT   EN

Ultimi tweet

ELCC 2017: latest news in lung cancer

Around 2,000 delegates from across Europe and worldwide will learn about the latest practice-changing science in the field of thoracic oncology at the seventh European Lung Cancer Conference (ELCC) in Geneva, Switzerland, from 5 to 8 May 2017.

Key themes at this year’s meeting include some of the most topical and keenly anticipated subjects, pertinent not only to lung cancer but to oncology as a whole – such as the latest advances in immunotherapy and screening, new steps in the treatment of molecularly defined NSCLC and the new IASLC staging. Over 220 abstracts were submitted to the conference.

Organised by ESMO and the IASLC (International Association for the Study of Lung Cancer), along with their partner societies ESTRO (European Society for Radiotherapy & Oncology) and ETOP (European Thoracic Oncology Platform), this conference brings together some of the most important organisations representing thoracic oncology specialists. Having grown year-on-year, ELCC is today considered to be the point of reference in the field of thoracic malignancies, providing a truly groundbreaking multidisciplinary programme.

ESMO co-chair Martin Reck, Germany, said: “ELCC is a multi-professional and interdisciplinary meeting which aims to present the latest advances in lung cancer. Nearly all key investigators of major trials will be at ELCC and we hope attendees will use this unique opportunity to discuss the exciting developments in lung cancer. It is my personal intention and hope that my colleagues will leave the conference optimistic about the new treatments available for their patients. Of course, we will also discuss ongoing challenges such as timely diagnosis and personalised medicine.”

IASCL co-chair Andrew Nicholson, UK, said “ELCC is hosted jointly by ESMO and the IASLC ensuring we share the latest information and facilitate exchanges between healthcare professionals committed to treating lung cancer patients. We are especially excited about the outcome of the latest IASLC staging project and discussing its impact on patient management.”

Media is invited to join the leading thoracic oncologists as they gather for state-of-the-art education and the latest advances in lung cancer treatment at this unique event.

Key themes for ELCC 2017:

  • Immunotherapy: first-line treatment, biomarkers and combination approaches
  • New steps in the treatment of molecularly defined NSCLC
  • SCLC and mesothelioma
  • Management and diagnosis of persistence in molecularly defined NSCLC
  • Management of brain metastases
  • New IASLC staging
  • ESMO recommendations for thoracic malignancies

 

Commenta questo articolo:

*
Il tuo indirizzo email non sarà visibile agli altri utenti.
Il commento sarà pubblicato solo previa approvazione del webmaster.